HARROW, INC.
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
About Harrow
Pharmaceutical Preparations, SIC 2834
Harrow, Inc. is an eye-care pharmaceutical company that specializes in the development, production, and commercialization of ophthalmic treatments and compounded medications. The company operates through two primary business segments: Branded and ImprimisRx. Its portfolio includes commercial ophthalmic therapies, notably VEVYE and IHEEZO, as well as specialized formulations. Harrow serves healthcare professionals, specialized clinics, hospitals, pharmacies, and patients requiring tailored pharmaceutical solutions.
The company conducts operations across several locations in the United States, maintaining office, laboratory, and facility spaces in Carlsbad, California; Ledgewood, New Jersey; and Nashville, Tennessee. The company's principal executive offices are headquartered in Nashville, Tennessee.
Summary of the business section of Harrow's latest annual report, written by StockData.
Company profile
Company
- Legal name
- HARROW, INC.
- Founded
- 1998
- Headquarters
- Nashville, TN
- Address
- 1a Burton Hills Blvd, Suite 200
- Phone
- (615) 733-4731
- Website
- www.harrow.com
- Employees
- 373, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KMJ Corbin & Company LLP, Glendora, California
Stock & identifiers
- Ticker
- HROW
- Exchange
- Nasdaq
- Shares outstanding
- 37M, Aug 6, 2026
- Public float
- $1.00B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-5 reverse, Mar 18, 2013; 1-for-5 reverse, Feb 8, 2013; 1-for-8 reverse, Feb 24, 2012
- SEC CIK
- 1360214
- CUSIP
- 415858109
- ISIN
- US4158581094
- LEI
- 529900AP4LIRLNV8A089
- EIN
- 45-0567010
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mark L. Baum | CHIEF EXECUTIVE OFFICER, Director | 3,594,256 |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | 0 |
| Andrew R. Boll | PRESIDENT AND CFO | 814,679 |
| Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | – |
| Francis William Mullery Jr | CEO, ImprimisRx | – |
| Randall E. Pollard | CHIEF ACCOUNTING OFFICER | – |
| John P. Saharek | CEO & President, ImprimisRx | 467,388 |
| Lauren P. Silvernail | Director | 1,000 |
| Perry J. Sternberg | Director | – |
| Adrienne L. Graves | Director | 1,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mark Baum | $23.61M | $33.13M | $3.56M | $714 | $120 |
| FY2025 Peo | $23.61M | – | $3.56M | $714 | $120 |
| FY2024 Mark Baum | $1.36M | $21.47M | $796.33K | $489 | $91 |
| FY2024 Peo | $1.36M | – | $796.33K | $489 | $91 |
| FY2023 Mark Baum | $15.26M | $3.11M | $6.47M | $163 | $92 |
| FY2023 Peo | $15.26M | – | $6.47M | $163 | $92 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of February 25, 2026, we employed 373 individuals.”
Corporate history
Events identified from SEC filings